Dominik Dahl
Hamburg, HH, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial.
Journal: Lancet (London, England)
Published: March 21, 2025
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.
Journal: The New England journal of medicine
Published: September 10, 2024
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.
Journal: Diabetes care
Published: December 09, 2022
A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Journal: Diabetes, obesity & metabolism
Published: July 24, 2022
Immunogenicity of the Novel Glucagon Analogue Dasiglucagon: Results of a Dedicated Immunogenicity Trial in Type 1 Diabetes.
Journal: Diabetes technology & therapeutics
Published: July 12, 2021
Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: October 07, 2020
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study.
Journal: Diabetes, obesity & metabolism
Published: March 25, 2020
Introduction of biosimilar insulins in Europe.
Journal: Diabetic medicine : a journal of the British Diabetic Association
Published: June 08, 2017
Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine.
Journal: Diabetes, obesity & metabolism
Published: October 14, 2015
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
Journal: Diabetes, obesity & metabolism
Published: February 13, 2015
Showing 1-11 of 11
Last Updated: 09/26/2026